Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug. Tasfygo (tasurgratinib succinate; formerly E7090), a small-molecule ...
Biliary tract cancer occurs in the bile ducts and gallbladder, with approximately 23,000 diagnoses in the US each year. Life expectancy is poor, with just 5% to 15% of patients expected to live ...